|
|
|
|
-
BioCryst Pharma Q1 Loss/Share Narrows To $0.09 From $0.13 Last Year; Provides Corporate Update
5/7/2013
|
-
BioCryst Pharma Completes Peramivir Type C Meeting
4/16/2013
|
|
|
|
|
|
|
-
BioCryst Pharma Provides Update Regarding Peramivir
4/1/2013
|
-
BioCryst Begins BCX4161 Phase 1 Clinical Trial To Treat Hereditary Angioedema
3/25/2013
|
|
|